Incyte Corporation (LON:0J9P)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 12.12B |
| Revenue (ttm) | 3.35B |
| Net Income (ttm) | 635.65M |
| Shares Out | n/a |
| EPS (ttm) | 3.19 |
| PE Ratio | 19.07 |
| Forward PE | 13.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 833 |
| Average Volume | 1,364 |
| Open | 84.69 |
| Previous Close | 83.22 |
| Day's Range | 83.15 - 84.69 |
| 52-Week Range | 53.61 - 90.13 |
| Beta | 0.75 |
| RSI | 58.38 |
| Earnings Date | Oct 28, 2025 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial numbers in USD Financial StatementsNews
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress.
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Incyte (INCY) Rating Affirmed with Increased Price Target by B of A Securities | INCY Stock News
Incyte (INCY) Rating Affirmed with Increased Price Target by B of A Securities | INCY Stock News
Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #HSTRUTHS--Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa.
Why Incyte Corp (INCY) Is Set to Outperform the Market: Insights into Financial Growth and ...
Why Incyte Corp (INCY) Is Set to Outperform the Market: Insights into Financial Growth and Competitive Advantage
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer.
Incyte to Present at Upcoming Investor Conferences
Incyte (NASDAQ: INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at ...
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.
20 stocks in the S&P 500 that are high achievers this earnings season
These companies have shown the largest increases in sales per share while also improving profit margins
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis.
Incyte (INCY) Leads Healthcare Gains Despite Market Dip
Incyte (INCY) Leads Healthcare Gains Despite Market Dip
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit...
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
Incyte Corporation 2025 Q2 - Results - Earnings Call Presentation
Incyte rises on results beat, lifted Jakafi guidance
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
Incyte Corporation (NASDAQ: INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion . Incyte’s adjusted ear...
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
Incyte Corporation INCY reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.